What Claritromycine Aurobindo Treats: Main Uses and Benefits

The medication is commonly used to help manage a variety of bacterial infections, supporting symptomatic relief and assisting in the management of acute episodes. This medication is generally used to help with infections affecting the respiratory system, skin, and stomach.

Claritromycine Aurobindo is relevant in contexts involving acute respiratory manifestations, including those associated with community-acquired pneumonia, acute flare-ups of chronic bronchitis, streptococcal pharyngitis, sinusitis, and acute otitis media. It is also applicable in conditions marked by visible, localized inflammatory manifestations like cellulitis and erysipelas, and is an integral part of specific multi-drug regimens designed for the management of Helicobacter pylori (H. pylori) bacteria.

The medication plays a role in managing symptom clusters that may appear suddenly and create noticeable physiological strain. It provides support that helps ease the overall symptom burden, contributing to general well-being during symptomatic phases.

“This application is relevant for easing symptomatic manifestations across domains involving heightened responses or specialized needs.”

---

Quick Fact: Supportive Symptom Management

Symptom Domain	Conditions Managed	Key Benefit
Respiratory	Pneumonia, Bronchitis, Sinusitis	Supports relief from cough and fever
Dermatological	Cellulitis, Erysipelas	Assists with reducing localized pain and swelling
Gastrointestinal	H. pylori associated Duodenal Ulcers	Contributes to reducing ulcer recurrence likelihood

Regulatory References

1. NIH MedlinePlus Drug Information

Claritromycine Aurobindo is strictly governed by regulatory eligibility criteria established by governmental health authorities. Use of this medication is absolutely contraindicated in several patient populations to prevent serious health risks.

Who Must NOT Use (Contraindications)	Restricted/Conditional Use
Patients with a known macrolide allergy or hypersensitivity.	Use requires caution in patients with impaired hepatic function.
Individuals with a history of cholestatic jaundice or hepatic dysfunction linked to prior macrolide use.	Patients with severe renal impairment (Creatinine Clearance < 30 mL/min) require a mandated dosage reduction.
Patients with pre-existing QT interval prolongation, ventricular cardiac arrhythmia, or uncorrected hypokalemia/hypomagnesemia.	Caution advised in patients with Myasthenia Gravis or specific pre-existing heart conditions, such as severe cardiac insufficiency.
Patients with severe hepatic failure combined with renal impairment.

The medication is not recommended for use in pregnant women, particularly during the first three months. For children, safety has not been established in infants under six months of age. Furthermore, film-coated tablets are not recommended for children under 12 years; the oral suspension should be used for this younger age group. Older adults with severe kidney impairment may also require a specific dosage adjustment.

Interactions with other medicines and products

The interaction profile of Claritromycine Aurobindo is defined by its role as an inhibitor of the CYP3A4 enzyme, a documented mechanism that leads to reduced clearance and increased plasma concentrations of numerous co-administered medicines.

Formally Contraindicated Combinations

Co-administration with several medicines is strictly prohibited (contraindicated) by regulatory labels due to the risk of severe adverse outcomes. These include:

• Cardiac Risk: Pimozide, Astemizole, Cisapride, and Terfenadine (due to risk of QT prolongation and ventricular arrhythmias).
• Myopathy Risk: Lovastatin and Simvastatin (due to increased risk of rhabdomyolysis). Therapy with these statins must be suspended during Clarithromycin treatment.
• Toxicity: Ergot alkaloids ( Ergotamine/ Dihydroergotamine) (due to risk of acute ergot toxicity/vasospasm), and Oral Midazolam (due to increased exposure).

Documented Pharmacodynamic and Food Interactions

Clarithromycin carries documented risks for pharmacodynamic toxicities. The combination with Colchicine is explicitly contraindicated in patients with renal or hepatic impairment due to heightened toxicity risk, which is also noted to be increased in the elderly. With regard to food, consumption with Clarithromycin tablets is documented to increase the peak plasma concentration ( Cmax) by approximately 24%; however, the overall extent of bioavailability is not significantly affected.

How Clarithromycin Aurobindo Works

Blocking Bacterial Protein Production

Clarithromycin Aurobindo acts by binding specifically to the 50S subunit of the bacterial ribosome . This action inhibits the step of protein synthesis (translation), blocking the ability of the bacteria to construct new proteins required for growth and division. The interaction type is classified as a reversible protein synthesis inhibitor.

Limiting Bacterial Proliferation

The disruption of protein production causes inhibition of bacterial growth, leading to a state where the bacterial population can no longer multiply (bacteriostasis). This mechanistic effect follows a downstream cascade from the initial molecular binding, resulting in a reduction of the replicating bacterial population size. This alteration in bacterial population dynamics influences the balance between the microbial presence and the host's endogenous immune activity.

The use of clarithromycin follows specific procedures defining the route, schedule, and handling of the medication. The product is primarily designated for oral administration, utilizing either film-coated tablets or granules prepared as an oral suspension.

Standard Administration Schedule

The standard dosing for immediate-release (IR) forms typically ranges from 250 mg to 500 mg per dose, taken every 12 hours (q12hr). For pediatric patients aged 6 months and older, a weight-based dose of 7.5 mg/kg per dose is used, utilizing the oral suspension.

Treatment duration is typically set between 6 and 14 days for most acute bacterial courses, though treatment for Streptococcus pyogenes infections specifies a minimum of 10 days. A key administration rule dictates that while IR tablets and suspensions may be taken without regard to food, the extended-release (ER) tablet formulation must be ingested with food.

Procedural Conditions

There are requirements for special handling. Extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed to maintain proper drug release. For adults diagnosed with severe renal impairment (creatinine clearance <30 mL/min), a dosage adjustment requires the daily amount to be reduced by 50%.

The standard procedure for a missed dose is to skip the missed dose and resume the regular schedule if it is almost time for the next dose; double doses must not be taken.

Evidence for Use in Respiratory and Ear Infections

Research examining this medicine was conducted for clinical situations such as Community-Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB), and Acute Otitis Media (AOM). Studies primarily involve Randomized Controlled Trials (RCTs) that monitored patient outcomes related to clinical status or improvement, as well as tracking physiological markers of systemic inflammation. Research included adult patient groups with varying disease severity. For AECB, comparative trials examined rates of achieving a measured clinical endpoint and bacteriologic clearance. Limitations noted in this evidence structure include the difficulty in separating the medicine's anti-infective effects from its non-antimicrobial properties.

---

Evidence for Use in Skin Infections and H. pylori Eradication

The evidence base for treating bacterial skin infections (SSTIs) like Cellulitis and Erysipelas includes Multicenter, Comparative Trials that focused on clinical efficacy measures. Specialized research, such as Pharmacokinetic/Pharmacodynamic (PK/PD) studies, explored the drug concentration patterns achieved within soft tissues. The role of this medicine in managing H. pylori bacteria is defined by Randomized, Controlled Trials that test its use only as part of a multi-drug triple therapy regimen. Primary endpoints examined are laboratory-confirmed H. pylori eradication rates and outcomes related to ulcer recurrence.

---

Research Focus and Uncertainty

The majority of clinical trials for acute infections monitor patient outcomes over a short-to-intermediate time frame (e.g., 7 to 90 days). Studies have evaluated the medicine in special populations, including children (for oral suspension) and subgroups of critically ill adults. While research is extensive, key uncertainties remain: the variability of eradication success in regions with high macrolide resistance, the full contribution of the anti-inflammatory action to clinical outcomes, and the general lack of data for specific narrow patient subgroups or very long-term outcomes.

Key Studies & References

1. 2024 American College Gastroenterology H. pylori Guidelines | Pharmacy
2. public assessment report (Used for general indications, formulations, and regulatory context)
3. Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA (Used for SSTI context and alternative uses like penicillin allergy)

Common questions about Claritromycine Aurobindo (FAQ)

Q: Is this drug a broad-spectrum antibiotic?

Claritromycine Aurobindo is classified as a semi-synthetic macrolide antibiotic. According to official regulatory information, this medicine is active in laboratory testing against a variety of aerobic and anaerobic gram-positive and gram-negative microorganisms, which defines its spectrum of activity.

Q: Is it true that this drug can cause a metallic taste, and what does it taste like?

Regulatory reports list dysgeusia, which is a distorted sense of taste, as a commonly reported undesirable effect. This taste disturbance has specifically been described in some patients as a metallic taste. Official product information also mentions that tongue discoloration has been reported in post-marketing experience.

Q: Can I take antacids (like milk of magnesia or aluminium hydroxide) at the same time as this drug?

Official regulatory studies involving a multi-drug regimen that included clarithromycin did not indicate a clinically significant drug interaction with a proton pump inhibitor. However, it is noted that the direct interaction of clarithromycin with common antacids like milk of magnesia or aluminium hydroxide may be specifically detailed in the official product labeling.

Q: Does this medication reduce the effectiveness of oral birth control pills?

Official regulatory documents do not identify claritromycine as interacting with oral contraceptives, and it is not listed as reducing their effectiveness.

Q: Can this drug be used to prevent infections, or is it only for treatment?

Official regulatory information states that in addition to treating certain existing bacterial infections, this medicine is also used to prevent and treat infections caused by Mycobacterium avium complex (MAC).

Q: What are the signs of an allergic reaction that mean I must stop taking the medicine immediately?

Official safety warnings state that immediate medical attention should be sought if signs of a serious allergic reaction are noticed. This includes swelling to the face, lips, mouth, throat, or neck that may cause difficulty in swallowing or breathing, or a sudden collapse. Other critical signs are noted to include a severe skin rash or yellowing of the eyes or skin (jaundice), which generally require stopping the medication and seeking immediate assistance.

Q: Is this drug safe to use in adolescents (12-18 years old)?

Regulatory information states this drug is indicated for the treatment of certain infections in adults and adolescents 12 years and older. The tablet form is generally not suitable for children under 12 years of age, who would typically require the oral suspension form.

Q: If I develop a rash, should I stop the medicine or call my doctor?

Official consumer medicine information advises that if any type of skin rash is noticed, discontinuation of the medicine is recommended, followed by contact with a healthcare professional. Emergency care may be advised if the rash is severe.

Q: Can this drug damage my hearing?

Official patient information advises that hearing disturbances should be reported to a healthcare team immediately. If hearing is affected while taking this medicine, urgent medical evaluation may be required.

Q: Can this medication affect my blood sugar levels?

Regulatory information indicates that people with diabetes may need to monitor blood sugar carefully while on this medication. This monitoring is noted as a precaution associated with certain antibiotics.

Q: Is this medicine safe for the elderly (people over 65)?

The regulatory recommended dose for the elderly is generally the same as for adults. However, official documents note that caution is warranted for older adults, particularly due to a potentially higher risk of serious adverse effects or if they have pre-existing heart, liver, or kidney problems.

Q: Does this drug interact with blood thinners like warfarin?

Official regulatory documentation indicates that the use of this medicine with warfarin (a type of blood thinner) carries a risk of serious hemorrhage (severe bleeding) and significant elevations in the INR (International Normalized Ratio) and prothrombin time.

Q: Should I be concerned about Clostridium difficile diarrhea while taking this?

Clostridioides difficile-associated diarrhoea (CDAD) is listed in official warnings for nearly all antibacterial agents, including clarithromycine. Regulatory documents state that the severity of this condition may range from mild diarrhoea to a serious, life-threatening inflammation of the colon (colitis).

Q: Should I avoid driving or operating machinery while taking this?

Official patient safety information advises that caution is warranted when driving or operating machinery, particularly until the effects of the medicine are known. This is based on the risk of side effects such as dizziness and headache.

Storage and Disposal of Clarithromycin Aurobindo

Official regulatory documents define strict conditions for the storage and disposal of Clarithromycin Aurobindo to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection	Keep the medicine in the original container and keep it tightly closed to protect it from moisture and light.
Child Safety	The medicine must be kept out of the sight and reach of children.

Stability and Disposal

The reconstituted oral suspension has an in-use stability of 14 days and must not be refrigerated. Unused or expired Clarithromycin Aurobindo must be disposed of according to local regulatory requirements. It is strictly prohibited to dispose of the medicine via wastewater (e.g., sink or toilet) or household waste.